ARC-7 (NCT04262856) is a randomized, open-label, phase 2 clinical trial that enrolled previously untreated patients with stage IV non-small-cell lung cancer expressing PD-L1 (TPS ≥ 50%). The gene discussed is CD274; the disease is non-small cell lung carcinoma.